Abhi is a well accomplished and results oriented healthcare and life sciences...Read more...
Patrick Soon-Shiong, MD, a physician, surgeon, researcher,...Read more...
Gauri is a biotechnologist with an extensive commercial research and...Read more...
Shahrooz Rabizadeh, PhD is the Chief Scientific Officer at...Read more...
Abhi is a well accomplished and results oriented healthcare and life sciences business leader with strong experience in Research, Product design and commercialization, Custom Software development, business eco systems development, Angel and Venture Investments, Sales and marketing, and building start-ups. Abhi has over 13 international patents to his credits. His experience includes Products, Medical Devices, BioInformatics Systems, BigData Analytics, Connected Devices and IoT, Visualization and Prediction, Machine Learning, Cancer Diagnostics and Image Informatics. Prior to founding OPTRA Group of companies, he was the founder of BioImagene, a digital pathology company that acquired Scimagix Inc., (2004) and Tissue Informatics Inc. (2006), before BioImagene was acquired by Roche Diagnostics for $100mn. Previously, Abhijeet was employed by TCS, Cedartech, and Siemens Medical Systems. Abhi is alumnus of Indian Institute of Technology (IIT) Mumbai with specialization in Biomedical Engineering. Abhi strongly believes in innovation and nurtures an entrepreneurial spirit in society at large. Abhi is charter member of TiE Silicon Valley and chairs Digital Healthcare SIG. He is also an honorary medical advisory member at Frost & Sullivan.
Over the years, Abhi and the companies he has founded, received a number of awards:
Gauri is a biotechnologist with an extensive commercial research and entrepreneurial background. Before founding Optra Systems, Inc., she was the founder and principal scientist at BioImagene Inc., a silicon valley based digital pathology company which was acquired by Roche Diagnostics. Gauri is responsible for enriching the domain knowledge of her companies, as well as involved in the strategic planning and business development activities. Gauri has extensive experience working in the genetics, cytology, microbiology, molecular biology, medical imaging and bioinformatics fields. Gauri was selected as a young scientist for various research programs in biotechnology and microbiology internationally. She has 11 U.S. patents published to her credit. She has published many research papers in international journals and has participated as a speaker in many international conferences. She is on the editorial and advisory boards of many prestigious journals and forums, including the Journal of Applied & Translational Genomics and the International Organization for Rare Genetic Disorders. Gauri was also awarded with the prestigious “Woman Entrepreneur Award" by the government of India.
Shahrooz Rabizadeh, PhD is the Chief Scientific Officer at NantOmics, LLC and at NantBioScience, Inc. Previously, he was the Director of Molecular Drug Discovery at Abraxis BioScience, Inc. and an Adjunct Assistant Professor of Bioengineering at UCLA. Prior to Abraxis, he co-directed the Discovery Translation Unit at the Buck Institute, where he also served as an Asst. Res. Professor. He received his PhD degree in Neuroscience at UCLA and trained as a Runyon Postdoctoral Fellow in Molecular Biology at Mass. General Hospital and Genetics at Harvard Medical School.
Patrick Soon-Shiong, MD, a physician, surgeon,
researcher, philanthropist and scientist, invented
and developed the revolutionary drug Abraxane,
which has received FDA approval for the treatment
of metastatic breast cancer, lung cancer and
advanced pancreatic cancer. Abraxane is the only
drug of its kind to be approved in first line
therapies across this broad spectrum of tumors in
both the U.S. and E.U. Over the course of Dr.
Soon-Shiong’s career, he has pioneered novel
therapies for both diabetes and cancer, published
over 100 scientific papers, and has issued over 200
patents worldwidefor groundbreaking
advancements spanning myriad fields of
technology and medicine. As a surgeon, Dr. Soon-Shiong performed the world’s first
encapsulated human islet transplant, the first engineered islet cell transplant and the first pig to
man islet cell transplant in diabetic patients.
In the early 1990’s, Dr. Soon-Shiong pursued the science of stem cell and nanotechnology at NASA, performing experiments as part of the Shuttle program. Soon-Shiong’s path to cancer research began while doing research for NASA that involved harnessing stem cells to make insulin. In 1991, he founded a biotechnology company to develop a novel nanoparticle anticancer drug with the concept of using “the tumors biology against itself”.
From 1997- 2010, Dr. Soon-Shiong served as founder, Chairman and CEO of two global pharmaceutical companies: American Pharmaceutical Partners and Abraxis BioScience. In 2008, Dr. Soon-Shiong sold American Pharmaceutical Partners (NASDAQ: APP) to Fresenius for approximately $4.6 billion and in 2010, sold Abraxis Bio Science to Celgene for approximately $3.8 billion.
In January 2016, Dr. Soon-Shiong announced the formation of Cancer MoonShot 2020, a comprehensive collaboration of researchers, insurers, academic institutions and pharmaceutical companies that seeks to accelerate the potential of combination immunotherapy in the treatment of cancer. The initiative has a goal of initiating Phase 2 trials in 20,000 cancer patients within the next four years in addition to launching a revolutionary molecular diagnostic test. Known as GPS Cancer, the test enables analysis of the whole genome and target proteomics, transcending genomics to the era of clinic proteomics in cancer.
Dr. Soon-Shiong currently serves as Chairman and CEO of NantWorks, an ecosystem of companies aiming to create transformative global health information and next-generation pharma development network. Under the NantWorks umbrella, Soon-Shiong also currently serves as Chairman and CEO of NantKwest (NK), a Nasdaq listed immunotherapy company focusing on Natural Killer cells, and Chairman and CEO of NantHealth (NH), a Nasdaq listed transformational healthcare company converging biomolecular medicine and bioinformatics with technology services to empower physicians, patients, payers, pharma and researchers to transcend the traditional barriers of today’s healthcare system.
Dr. Soon-Shiong is Chairman of the Chan Soon-Shiong Family Foundation and of the Chan Soon-Shiong Institute of Molecular Medicine, a non-profit medical research organization. He co-chairs the CEO Council for Health and Innovation at the Bipartisan Policy Center, is the Executive Director of the UCLA Wireless Health Institute and is a member of the Global Advisory Board of Bank of America. He also is an Adjunct Professor of Surgery at UCLA, a visiting Professor at the Imperial College of London, and a Professor of Microbiology, Immunology & Molecular Genetics and Professor of Bioengineering at the California NanoSystems Institute of UCLA. The Friends of the National Library of Medicine has honored him with their Distinguished Medical Science Award.
In April 2016, Dr. Soon-Shiong received the Franklin Institute Award for his visionary leadership and commitment to advancing medical and scientific research and bringing new treatment options to cancer patients. Dr. Soon-Shiong was also honored at the Vatican in April 2016 and received the 2016 Pontifical Key Visionary Award. The award recognizes “medical innovators who change the course of history and reduce suffering on a global scale by blending visionary thinking with real action”.
Born and raised during apartheid in South Africa, Dr. Soon-Shiong resides in Los Angles and is a citizen of the United States.
Prasad is a qualified CPA, CS and CWA, with more than 20 years experience in the IT and Industrial space. His key areas of focus have been Operational Review and Analysis (Project Profitability, Degree of Bench, etc.), Financial Management (Accounts / Audit / Taxation), Legal (STPI, FEMA, etc.), HR, ISO and Secretarial Compliance, thereby contributing to the interests of all stakeholders. He has experience in the Software Field (ITeS), including securing VC Funding, Fiscal Monitoring and Managing Operations of the India Business Unit (Legal, HR, Infrastructure and Admin). He has initiated and successfully implemented the Accounting of Subsidiary Companies on a US-based GAAP (US and India) compliant Package for Seamless Consolidation.